Home › Trial NCT05673967
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
- Trial IDNCT05673967
- StatusCompleted
- PhaseN/A
- Study typeObservational
- SponsorRegeneron Pharmaceuticals
- Enrollment62
- Start date2023-01-09
- ConditionsRelapsed and Refractory Multiple Myeloma (RRMM)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.